We presented Treatments that made headlines in hematology in 2018. From  Nature Medicine 24,1785–1787 (2018) Presenter: Prof. Spyridonidis Paricipants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris   Green light CD19 CAR therapy Chimeric antigen receptor (CAR) therapy using the CD19 antigen continued to show its benefits after a long-term follow-up study found that...

Early-Stage Follicular Lymphoma: What Is the Preferred Treatment  Strategy  in Early-Stage Follicular Lymphoma? WW, RT, Chemo,  Immunoterpay or a combination of the above? Porobaly lla are the saem  iof one consideres OS as outocem,but may differ in regard to EFS.   A critical opinion on a randomized study...

A Japanese study questioned the "favorable" status of AML with low  allelic ratio FLT3-ITD and NPM1 mutation given by ELN criteria. Flt3 mut  presence is a clear indication for AML. Presenter:Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris

Which is the best conditioning in ALL? Slides that we presented in  EBMT ALWP in Krakow 2018. The slides present the current policy in Patras. Presenter: Prof.Spyridonidis Pariticpants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris              

We review again the BK cystitis and our current SOPs. We discussed the  initiation of a prosepctive study with intravesicular cidofovir. Presenter: Prof. Spyridondis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris

Retrospective studies indicating that specific comorbidities are  associated with increased NRM in specific conditoning regimens. For  example cardiac disease is high toxic in BUFlu regimens. These results have been implemented in our daily clinical praxis. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris.    

We presented the Consensus of North American Experts regarding MRD in ALL Management and the algorithm for allo/HSCT. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris.

We discussed the results of a randomized study on Azacitidine with or  without eltrombopag for first-line treatment of intermediate- or  high-risk MDS with thrombocytopenia. The study was closed premature because of a negative effect of  eltromombag both on thrombocytopenia and time to progress to AML. Presenter: Prof. Spyridonidis Participants: Dr...

The updated results of the Aethera study were presented which confirmed  the effect of consolidation on PFS. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris.

1. The optimal time for MRD testing may depend on the type of MRD. CBFB-MYH11 AML displayed a slower clone regrowth than AML with the other molecular signatures and recommended MRD testing for CBFB-MYH11 be performed every 6 months, whereas testing for PML-RARA MRD was recommended for every 2 months.   2. Another subject of...

We discussed a paper in which the authors measured MRD in AML by NGS  before allo Tx. They could perfom MRD analysis in most cases and MRD by  NGS proved the strongest factor for relapse post HCT. Presenter:  Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka,...

We updated the current options for the treatment of CNS NHL and reviewed a  patient series (5 pts) treated with nivolumab for rrCNS NHL. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris

The mechanisms of glucocorticoid induced leukocytosis were revealed during the discussion. TITLE: A general review of the mechanisms for steroid or glucocorticoid induced increases in the white blood cell count, Anthony J Busty, MD, PharmD, FNLA, FAHA.  Link: https://www.ebmconsult.com/articles/steroids-glucocorticoids-wbc-neutrophiles-increase Presenter:Dr Bountouris Participants: Prof. Spyridonidis, Dr Liga, Dr Spyridis,...

The treatment of DCIS T2N0M0 type of breast cancer was discussed and it was noted that after total mastectomy radiation is not needed. Presenter: Dr Bountouris Participants: Prof. Spyridonidis, Dr Liga, Dr Spyridis, Dr Lekka.

We discussed the evaluation and differential diagnosis of pineal tumors in adults, focusing on the pinocytomas.   Presenter: Dr Bountouris. Participants: Prof.Spyridonidis, Dr Liga, Dr Spyridis, Dr Lekka.

The excellent review from Zeieser and  Blazar on chronic GvHD published  in NEJM was discussed. Presenter: Prof. Spyridonidis Participants: Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris

We discussed the central role of B cell activation in chronic GVHD and  discussed the results of ibrutinib in cGVHD which led to FDA approval. Presenter: Prof. Spyridonidis Participants. Dr Liga, Dr Spyridis, Dr Lekka, Dr Bountouris